eye health

Novartis says glaucoma stent setback will not derail Alcon spin-off
Novartis says glaucoma stent setback will not derail Alcon spin-off
Yahoo/Reuters
Novartis
glaucoma
Alcon
eye health
devices
CyPass Micro-Stent
Flag link:
FDA approves Kala's twice-daily ocular steriod
FDA approves Kala's twice-daily ocular steriod
BioCentury
Kala Pharmaceuticals
Inveltys
ocular steriods
eye health
Flag link:
Novartis to spin out Alcon ophthalmic subsidiary
Novartis to spin out Alcon ophthalmic subsidiary
Mass Device
Novartis
Alcon
opthalmology
eye health
devices
spinoffs
Flag link:
Report: Johnson & Johnson sees Vision Care biz grow, looks to expand beyond contacts
Report: Johnson & Johnson sees Vision Care biz grow, looks to expand beyond contacts
Mass Device
JNJ
eye health
Flag link:
Drug companies want Supreme Court to take eye drop dispute
Drug companies want Supreme Court to take eye drop dispute
Yahoo/AP
eye drops
eye health
Supreme Court
Allergan
Bausch & Lomb
Merck
Pfizer
Flag link:
Apellis touts new data for eye drug hopeful
Apellis touts new data for eye drug hopeful
Biopharma Dive
Apellis
eye health
APL-2
age-related macular degeneration
Flag link:
J&J Vision to acquire TearScience
J&J Vision to acquire TearScience
Mass Device
JNJ
TearScience
M&A
eye health
ophthalmology
Flag link:
Novartis unit Alcon posts modest Q2 gain
Novartis unit Alcon posts modest Q2 gain
Mass Device
Novartis
Alcon
eye health
earnings
devices
Flag link:
Potential Alcon sale worries Novartis investors
Potential Alcon sale worries Novartis investors
Drug Delivery Business News
Novartis
Alcon
devices
M&A
eye health
Flag link:
Horizon dives into eye treatments with River Visions acquisition
Horizon dives into eye treatments with River Visions acquisition
BioPharma Dive
Horizon Pharma
River Visions
M&A
eye health
Flag link:
Horizon Pharma buys River Vision and its fast-tracked eye med for $145M
Horizon Pharma buys River Vision and its fast-tracked eye med for $145M
Fierce Biotech
Horizon Pharma
River Vision
eye health
teprotumumab
thyroid eye disease
Flag link:
1Q17 Earnings for Novartis’s Alcon, Its Eye Care Business
1Q17 Earnings for Novartis’s Alcon, Its Eye Care Business
Market Realist
Novartis
earnings
Alcon
eye care
eye health
Flag link:
Novartis’s 1Q17 Estimates for Alcon
Novartis’s 1Q17 Estimates for Alcon
Market Realist
Novartis
Alcon
earnings
eye health
Flag link:
Ocular touts patient experience data for Dextenza implant
Ocular touts patient experience data for Dextenza implant
Drug Delivery Business News
devices
Ocular Therapeutix
eye health
Dextenza
post-surgical pain
Flag link:
Allergan antes up $90M in a CRISPR/Cas9 collaboration with Editas on eye diseases
Allergan antes up $90M in a CRISPR/Cas9 collaboration with Editas on eye diseases
Endpoints
Allergan
eye health
CRISPR-Cas9
Editas
Flag link:
Nicox resubmits eye drug to FDA after manufacturing setback
Nicox resubmits eye drug to FDA after manufacturing setback
BioPharma Dive
NicOx
FDA
Zerviate
eye health
Flag link:
Johnson & Johnson closes $4.3B Abbott Medical Optics buy
Johnson & Johnson closes $4.3B Abbott Medical Optics buy
Mass Device
JNJ
devices
M&A
Abbott Medical Optics
eye health
Flag link:
Valeant Acquires Eyegate Licensing Rights
Valeant Acquires Eyegate Licensing Rights
TheStreet.com
Valeant Pharmaceuticals
EyeGate Pharma
eye health
devices
Flag link:
Ocular Therapeutix touts data from phase III trial of Dextenza
Ocular Therapeutix touts data from phase III trial of Dextenza
Mass Device
Ocular Therapeutix
Dextenza
devices
post-surgical ocular inflammation and pain
eye health
Flag link:
FDA clears Allergan’s Xen gel stent for glaucoma
FDA clears Allergan’s Xen gel stent for glaucoma
Mass Device
FDA
Allergan
Xen gel stent
glaucoma
devices
eye health
Flag link:

Pages